195 related articles for article (PubMed ID: 28876454)
1. Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX.
Iwai T; Yamada T; Koizumi M; Shinji S; Yokoyama Y; Takahashi G; Takeda K; Hara K; Ohta K; Uchida E
J Surg Oncol; 2017 Dec; 116(7):947-953. PubMed ID: 28876454
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.
Ohta R; Yamada T; Hara K; Iwai T; Tanakaya K; Ishibashi K; Yoshimatsu K; Kosugi C; Tsubaki M; Nakajima H; Oya M; Yoshida H; Koda K; Ishida H
Int J Clin Oncol; 2020 Dec; 25(12):2075-2082. PubMed ID: 32785799
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.
Machida N; Yoshizaki K; Boku N; Yamazaki K; Onozawa Y; Fukutomi A; Yasui H; Taku K
Int J Clin Oncol; 2013 Apr; 18(2):279-84. PubMed ID: 22367535
[TBL] [Abstract][Full Text] [Related]
4. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Stevenson HL; Prats MM; Sasatomi E
BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
[TBL] [Abstract][Full Text] [Related]
6. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
[TBL] [Abstract][Full Text] [Related]
8. Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
Kim MJ; Han SW; Lee DW; Cha Y; Lee KH; Kim TY; Oh DY; Kim SH; Im SA; Bang YJ; Kim TY
Cancer Res Treat; 2016 Jul; 48(3):990-7. PubMed ID: 26790967
[TBL] [Abstract][Full Text] [Related]
9. [Two cases of advanced colorectal cancer which demonstrated the reversibility of oxaliplatin-mediated increase in splenic volume].
Motoori S; Kawase T; Nishimura H; Hosokawa Y; Konno T; Hanai C; Kitagawa N; Saisho H; Furuse J
Gan To Kagaku Ryoho; 2011 Apr; 38(4):677-80. PubMed ID: 21499004
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
11. [Adjuvant chemotherapy comprising modified FOLFOX6 after curative resection of synchronous or metachronous metastasis from colorectal cancer].
Hatano S; Ishibashi K; Amano K; Ishiguro T; Kuwabara K; Sobajima J; Ohsawa T; Okada N; Kumagai Y; Kumamoto K; Baba H; Tsuji Y; Haga N; Ishida H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2192-4. PubMed ID: 23268020
[TBL] [Abstract][Full Text] [Related]
12. [Sinusoidal obstruction syndrome induced by FOLFOX adjuvant chemotherapy].
Chaput U; Coriat R; Terris B; Brezault C; Chaussade S
Gastroenterol Clin Biol; 2008 Dec; 32(12):992-4. PubMed ID: 19019605
[No Abstract] [Full Text] [Related]
13. [Liver damage detected after a hepatectomy for liver metastasis after 12 courses of mFOLFOX6 therapy as an adjuvant chemotherapy for colorectal cancer].
Makino S; Murata K; Murakami M; Wada Y; Kato R; Nishigaki T; Owada Y; Okada K; Yanagisawa T; Okamura S; Ebisui C; Yokouchi H; Kinuta M; Nakagomi N; Tamai M
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2222-4. PubMed ID: 23268030
[TBL] [Abstract][Full Text] [Related]
14. Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.
Cercek A; Siegel CL; Capanu M; Reidy-Lagunes D; Saltz LB
Clin Colorectal Cancer; 2013 Sep; 12(3):163-7. PubMed ID: 23871161
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
[TBL] [Abstract][Full Text] [Related]
16. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
19. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
Hubert C; Lucidi V; Weerts J; Dili A; Demetter P; Massart B; Komuta M; Navez J; Reding R; Gigot JF; Sempoux C
Eur J Surg Oncol; 2018 Oct; 44(10):1532-1538. PubMed ID: 30093084
[TBL] [Abstract][Full Text] [Related]
20. [Assessment of host status in patients treated with mFOLFOX6 adjuvant chemotherapy after colorectal cancer surgery].
Sagawa M; Yoshimatsu K; Yokomizo H; Osawa G; Matsumoto A; Yano Y; Nakayama M; Yamaguchi K; Shiozawa S; Shimakawa T; Katsube T; Naritaka Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1587-9. PubMed ID: 24393857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
